Product Pipeline

Allergy Therapeutics research and development programmes aim to maximise safe and effective products for the treatment of allergy. We currently have Phase II  and Phase III clinical programmes underway as well as a range of preclinical research activities.

In this section you will find out more about our R&D efforts as well as an introduction to the novel adjuvant Monophosphoryl Lipid A (MPL®) and its use in our allergy vaccines.

The Most Advanced Allergy Immunotherapy Development Programme – Worldwide